Evaluation of Study Experiences of Neuroendocrine Tumor Patients

Taking part in clinical trials usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.

This research will admit a wide range of data on the clinical study experience of neuroendocrine tumor patients to determine which factors prevail in limiting a patient's ability to join or finish a trial.

It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future patients with neuroendocrine tumor.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Neuroendocrine Tumors Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue Neuroectodermal Tumors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Power Life Sciences

San Francisco, California, 94107, United States

Location contact

Michael B Gill

CONTACT

https://www.withpower.com/[email protected]

415-900-4227

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patient is at least 18 years of age
Diagnosis of neuroendocrine tumor
Ability to understand and the willingness to sign a written informed consent document

Exclusion criteria

Enrolled in another research study
Patients with psychiatric illness/social situations that would limit compliance with study requirements
Pregnant or lactating woman

Treatment and study plan

Primary outcomes

Rate of patients who decide to join in a neuroendocrine tumor clinical research

Time frame: 3 months
Number of neuroendocrine tumor patients who remain in clinical trial until completion

Time frame: 12 months

Study contacts

Contact information is provided by the study sponsor or research team.

Michael B Gill

CONTACT

[email protected]

4159004227

Sponsors and collaborators

Lead sponsor

Power Life Sciences Inc.

Industry

Registry information

Official study title

Investigating the Clinical Trial Journey and Engagement of Neuroendocrine Tumor Patients

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2026
First posted: Aug 1, 2023
Registry last updated: Aug 1, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting